systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075082X.2020.2.200126systhiper-621Research ArticleРЕКОМЕНДАЦИИGUIDELINESКлинические рекомендации. Диагностика, лечение и профилактика артериальной гипертензии у детей и подростковClinical guidelines on arterial hypertension diagnosis, treatment and prevention in children and adolescentsАлександровА. А.AleksandrovA. A.info@eco-vector.comКислякО. А.KisliakO. A.info@eco-vector.comЛеонтьеваИ. В.LeontyevaI. V.info@eco-vector.com202023122022172735Copyright © Александров А.А., Кисляк О.А., Леонтьева И.В., 20222022Александров А.А., Кисляк О.А., Леонтьева И.В.Aleksandrov A.A., Kisliak O.A., Leontyeva I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/621

Сердечно-сосудистые заболевания (ССЗ) занимают ведущее место в структуре неинфекционной патологии взрослых и являются основной причиной ранней инвалидизации и преждевременной смерти в большинстве экономически развитых стран. По данным последних эпидемиологических исследований, отмечается значительный рост как высокого нормального артериального давления (АД), так и артериальной гипертензии (АГ) среди детей и подростков. В наибольшей степени это относится к детям подросткового возраста, при этом АГ выявляется от 4 до 22% обследованных в зависимости от возраста обследованных и избранных критериев.

Cardiovascular diseases (CVD) occupy a leading place in the structure of non-infectious pathology in adults and are the main cause of early disability and premature death in most economically developed countries. According to recent epidemiological studies, there has been a significant increase in both high normal blood pressure (BP) and arterial hypertension (AH) among children and adolescents. This applies to the greatest extent to adolescent children, while AH is detected from 4 to 22% of those surveyed, depending on the age of the surveyed and the selected criteria.

артериальная гипертензияартериальное давлениецелевые значения артериального давленияизмерение артериального давлениясердечно-сосудистые осложнениясердечно-сосудистый рискдетиподросткирекомендацииобраз жизнипоражение органов-мишенеймедикаментозное лечениеarterial hypertensionblood pressureblood pressure target valuesblood pressure measurementcardiovascular complicationscardiovascular riskchildrenadolescentsguidelineslifestyletarget organs damagepharmacological therapyReferencesЧазова И.Е., Жернакова Ю.Е. Клинические рекомендации. Диагностика, лечение артериальной гипертензии. Системные гипертензии. 2019; 16: 6-31.Чазова И.Е., Жернакова Ю.Е. Клинические рекомендации. Диагностика, лечение артериальной гипертензии. Системные гипертензии. 2019; 16: 6-31.Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 00: 1-98.Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 00: 1-98.Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика. 2009; 8 (4; Прил. 1): 1-32.Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика. 2009; 8 (4; Прил. 1): 1-32.Александров А.А., Бубнова М.Г., Кисляк О.А. и др. Профилактика сердечно-сосудистых заболеваний в детском и подростковом возрасте. Российские рекомендации. Рос. кардиол. журн. 2012; 6 (Прил. 1): 1-40Александров А.А., Бубнова М.Г., Кисляк О.А. и др. Профилактика сердечно-сосудистых заболеваний в детском и подростковом возрасте. Российские рекомендации. Рос. кардиол. журн. 2012; 6 (Прил. 1): 1-40Lurbe E, Agabiti-Roseic E, Cruickshankd JK et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34 (10): 1887-920. DOI: 10.1097/HJH.0000000000001039Lurbe E, Agabiti-Roseic E, Cruickshankd JK et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34 (10): 1887-920. DOI: 10.1097/HJH.0000000000001039Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension 2013; 62 (2): 247-54.Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension 2013; 62 (2): 247-54.Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140 (3): e20171904.Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140 (3): e20171904.Kelishadi R, Mirmoghtadaee P, Najafi H, Keikha M. Systematic review on the association of abdominal obesity in children and adolescents with risk factors. J Res Med Sci 2015; 20 (3): 294-307.Kelishadi R, Mirmoghtadaee P, Najafi H, Keikha M. Systematic review on the association of abdominal obesity in children and adolescents with risk factors. J Res Med Sci 2015; 20 (3): 294-307.Friedemann C, Heneghan C, Mahtani K et al. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ 2012; 345: e4759.Friedemann C, Heneghan C, Mahtani K et al. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ 2012; 345: e4759.Flechtner-Mors M, Neuhauser H, Reinehr T et al., APV initiative and the BMBF Competence Network Obesity. Blood pressure in 57,915 pediatric patients who are overweight or obese based on five reference systems. Am J Cardiol 2015; 115: 1587-94.Flechtner-Mors M, Neuhauser H, Reinehr T et al., APV initiative and the BMBF Competence Network Obesity. Blood pressure in 57,915 pediatric patients who are overweight or obese based on five reference systems. Am J Cardiol 2015; 115: 1587-94.Parker ED, Sinaiko AR, Kharbanda EO et al. Change in weight status and development of hypertension. Pediatrics 2016; 137 (3): e20151662Parker ED, Sinaiko AR, Kharbanda EO et al. Change in weight status and development of hypertension. Pediatrics 2016; 137 (3): e20151662Koebnick C, Black MH, Wu J et al. High blood pressure in overweight and obese youth: implications for screening. J Clin Hypertens (Greenwich) 2013; 15 (11): 793-805.Koebnick C, Black MH, Wu J et al. High blood pressure in overweight and obese youth: implications for screening. J Clin Hypertens (Greenwich) 2013; 15 (11): 793-805.Zhang T, Zhang H, Li S et al. Impact of adiposity on incident hypertension is modified by insulin resistance in adults: longitudinal observation from the Bogalusa Heart Study. Hypertension 2016; 67 (1): 56-62.Zhang T, Zhang H, Li S et al. Impact of adiposity on incident hypertension is modified by insulin resistance in adults: longitudinal observation from the Bogalusa Heart Study. Hypertension 2016; 67 (1): 56-62.Kaelber DC. IBM explorys cohort discovery tool. www.ibm.com/watson/health/explorysKaelber DC. IBM explorys cohort discovery tool. www.ibm.com/watson/health/explorysHalbach SM, Martz K, Mattoo T, Flynn J. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr 2012; 160 (4): 621-5.Halbach SM, Martz K, Mattoo T, Flynn J. Predictors of blood pressure and its control in pediatric patients receiving dialysis. J Pediatr 2012; 160 (4): 621-5.Hartzell K, Avis K, Lozano D, Feig D. Obstructive sleep apnea and periodic limb movement disorder in a population of children with hypertension and/or nocturnal nondipping blood pressures. J Am Soc Hypertens 2016; 10 (2): 101-7.Hartzell K, Avis K, Lozano D, Feig D. Obstructive sleep apnea and periodic limb movement disorder in a population of children with hypertension and/or nocturnal nondipping blood pressures. J Am Soc Hypertens 2016; 10 (2): 101-7.Archbold KH, Vasquez MM, Goodwin JL, Quan SF. Effects of sleep patterns and obesity on increases in blood pressure in a 5-year period: report from the Tucson Children’s Assessment of Sleep Apnea Study. J Pediatr 2012; 161 (1): 26-30.Archbold KH, Vasquez MM, Goodwin JL, Quan SF. Effects of sleep patterns and obesity on increases in blood pressure in a 5-year period: report from the Tucson Children’s Assessment of Sleep Apnea Study. J Pediatr 2012; 161 (1): 26-30.Au CT, Ho CK, Wing YK et al. Acute and chronic effects of sleep duration on blood pressure. Pediatrics 2014; 133 (1). www.pediatrics.org/cgi/content/full/133/1/e64Au CT, Ho CK, Wing YK et al. Acute and chronic effects of sleep duration on blood pressure. Pediatrics 2014; 133 (1). www.pediatrics.org/cgi/content/full/133/1/e64The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (2 Suppl.): 555-76.The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (2 Suppl.): 555-76.O’Brien E, Parati G, Stergiou G et al., European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31: 1731-68.O’Brien E, Parati G, Stergiou G et al., European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31: 1731-68.Wuhl E, Witte K, Soergel M et al., German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002; 20: 1995-2007.Wuhl E, Witte K, Soergel M et al., German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002; 20: 1995-2007.Mitsnefes M, Flynn J, Cohn S et al; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21 (1): 137-44.Mitsnefes M, Flynn J, Cohn S et al; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21 (1): 137-44.Lurbe E, Thijs L, Torro MI et al. Sexual dimorphism in the transition from masked to sustained hypertension in healthy youths. Hypertension 2013; 62: 410-4.Lurbe E, Thijs L, Torro MI et al. Sexual dimorphism in the transition from masked to sustained hypertension in healthy youths. Hypertension 2013; 62: 410-4.Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics 2008; 122 (6): 1177-81.Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics 2008; 122 (6): 1177-81.Valent-Morić B, Zigman T, Zaja-Franulović O et al. The importance of ambulatory blood pressure monitoring in children and adolescents. Acta Clin Croat 2012; 51 (1): 59-64.Valent-Morić B, Zigman T, Zaja-Franulović O et al. The importance of ambulatory blood pressure monitoring in children and adolescents. Acta Clin Croat 2012; 51 (1): 59-64.Kavey RE, Kveselis DA, Atallah N, Smith FC. White coat hypertension in childhood: evidence for end-organ effect. J Pediatr 2007; 150 (5): 491-7.Kavey RE, Kveselis DA, Atallah N, Smith FC. White coat hypertension in childhood: evidence for end-organ effect. J Pediatr 2007; 150 (5): 491-7.Dionne J et al. Pediatric Nephrology Hypertension in infancy: diagnosis, management and outcome. 2012; 27 (1): 17-32.Dionne J et al. Pediatric Nephrology Hypertension in infancy: diagnosis, management and outcome. 2012; 27 (1): 17-32.Bochud M, Bovet P, Elston RC et al. High heritability of ambulatory blood pressure in families of East African descent. Hypertension 2005; 45: 445-50.Bochud M, Bovet P, Elston RC et al. High heritability of ambulatory blood pressure in families of East African descent. Hypertension 2005; 45: 445-50.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219. DOI: 10.1093/eurheartj/eht151Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219. DOI: 10.1093/eurheartj/eht151Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 2009; 22: 709-14.Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 2009; 22: 709-14.Moller NC, Grontvve A, Wedderkopp N. Cardiovascular disease risk factors and blood pressure response during in exercise during in health children and adolescents the European Youth Heart study. J Appl Physiol 2010; 109: 1125-32.Moller NC, Grontvve A, Wedderkopp N. Cardiovascular disease risk factors and blood pressure response during in exercise during in health children and adolescents the European Youth Heart study. J Appl Physiol 2010; 109: 1125-32.Аверьянов С.Н., Амчеславский В.Г., Багаев В.Г., Тепаев Р.Ф. Определение скорости клубочковой фильтрации у детей: история и современные подходы. Педиатрическая фармакология. 2018; 15 (3): 218-23. DOI: 10.15690/pf.v15i3.1901.Аверьянов С.Н., Амчеславский В.Г., Багаев В.Г., Тепаев Р.Ф. Определение скорости клубочковой фильтрации у детей: история и современные подходы. Педиатрическая фармакология. 2018; 15 (3): 218-23. DOI: 10.15690/pf.v15i3.1901.Lubrano R, Travasso E, Raggi C et al. Blood pressure load, proteinuria and renal function in prehypertensive children. Pediatr Nephrol 2009; 24: 823-31.Lubrano R, Travasso E, Raggi C et al. Blood pressure load, proteinuria and renal function in prehypertensive children. Pediatr Nephrol 2009; 24: 823-31.Flynn J, Zhang Y, Solar-Yohay S, Shi V. Clinical and demographic characteristics of children with hypertension. Hypertension 2012; 60 (4): 1047-54.Flynn J, Zhang Y, Solar-Yohay S, Shi V. Clinical and demographic characteristics of children with hypertension. Hypertension 2012; 60 (4): 1047-54.Agarwal A, Kapur G, Altinok D. Childhood posterior reversible encephalopathy syndrome: magnetic resonance imaging findings with emphasis on increased leptomeningeal FLAIR signal. Neuroradiol J 2015; 28: 638-43.Agarwal A, Kapur G, Altinok D. Childhood posterior reversible encephalopathy syndrome: magnetic resonance imaging findings with emphasis on increased leptomeningeal FLAIR signal. Neuroradiol J 2015; 28: 638-43.Hager A, Kanz S, Kaemmerer H et al. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. J Thorac Cardiovasc Surg 2007; 134 (3): 738-45.Hager A, Kanz S, Kaemmerer H et al. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. J Thorac Cardiovasc Surg 2007; 134 (3): 738-45.Di Salvo G, Castaldi B, Baldini L et al. Masked hypertension in young patients after successful aortic coarctation repair: impact on left ventricular geometry and function. J Hum Hypertens 2011; 25: 739-45.Di Salvo G, Castaldi B, Baldini L et al. Masked hypertension in young patients after successful aortic coarctation repair: impact on left ventricular geometry and function. J Hum Hypertens 2011; 25: 739-45.Giordano U, Cifra B, Giannico S et al. Mid-term results, and therapeutic management, for patients suffering hypertension after surgical repair of aortic coarctation. Cardiol Young 2009; 19: 451-5.Giordano U, Cifra B, Giannico S et al. Mid-term results, and therapeutic management, for patients suffering hypertension after surgical repair of aortic coarctation. Cardiol Young 2009; 19: 451-5.Moltzer E, Mattace Raso FU, Karamermer Y et al. Comparison of candesartan versus metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J Cardiol 2010; 105: 217-22.Moltzer E, Mattace Raso FU, Karamermer Y et al. Comparison of candesartan versus metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J Cardiol 2010; 105: 217-22.Baracco R, Kapur G, Mattoo T et al. Prediction of primary vs secondary hypertension in children. J Clin Hypertens (Greenwich) 2012; 14 (5): 316-21.Baracco R, Kapur G, Mattoo T et al. Prediction of primary vs secondary hypertension in children. J Clin Hypertens (Greenwich) 2012; 14 (5): 316-21.Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128: S213-256. DOI: 10.1542/peds.2009-2107CExpert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128: S213-256. DOI: 10.1542/peds.2009-2107CElkins C, Fruh S, Jones L, Bydalek K. Clinical Practice Recommendations for Pediatric Dyslipidemia. J Ped Health Care 2019; 33 (4): 494-504.Elkins C, Fruh S, Jones L, Bydalek K. Clinical Practice Recommendations for Pediatric Dyslipidemia. J Ped Health Care 2019; 33 (4): 494-504.Zimmet P, Alberti KG, Kaufman F et al; IDF Consensus Group. The metabolic syndrome in children and adolescents an IDF consensus report. Pediatr Diabetes 2007; 8 (5): 299-306.Zimmet P, Alberti KG, Kaufman F et al; IDF Consensus Group. The metabolic syndrome in children and adolescents an IDF consensus report. Pediatr Diabetes 2007; 8 (5): 299-306.Torrance B, McGuire KA, Lewanczuk R, McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. Vasc Health Risk Manag 2007; 3 (1): 139-49.Torrance B, McGuire KA, Lewanczuk R, McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. Vasc Health Risk Manag 2007; 3 (1): 139-49.Farpour-Lambert NJ, Aggoun Y, Marchand LM et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54 (25): 2396-406. DOI: 10.1016/j.jacc.2009.08.030Farpour-Lambert NJ, Aggoun Y, Marchand LM et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54 (25): 2396-406. DOI: 10.1016/j.jacc.2009.08.030Kelley GA, Kelley KS, Tran ZV. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003; 6 (1): 8-16.Kelley GA, Kelley KS, Tran ZV. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003; 6 (1): 8-16.Tompkins CL, Moran K, Preedom S, Brock DW. Physical activity-induced improvements in markers of insulin resistance in overweight and obese children and adolescents. Curr Diabetes Rev 2011; 7 (3): 164-70.Tompkins CL, Moran K, Preedom S, Brock DW. Physical activity-induced improvements in markers of insulin resistance in overweight and obese children and adolescents. Curr Diabetes Rev 2011; 7 (3): 164-70.Damasceno MM, de Araújo MF, deFreitas RW et al. The association between blood pressure in adolescents and the consumption of fruits, vegetables and fruit juice--an exploratory study. J Clin Nurs 2011; 20 (11-12): 1553-60.Damasceno MM, de Araújo MF, deFreitas RW et al. The association between blood pressure in adolescents and the consumption of fruits, vegetables and fruit juice--an exploratory study. J Clin Nurs 2011; 20 (11-12): 1553-60.Saneei P, Hashemipour M, Kelishadi R et al. Effects of recommendations to follow the dietary approaches to stop hypertension (DASH) diet v. usual dietary advice on childhood metabolic syndrome: a randomized cross-over clinical trial. Br J Nutr 2013; 110 (12): 2250-9. DOI: 10.1017/S0007114513001724Saneei P, Hashemipour M, Kelishadi R et al. Effects of recommendations to follow the dietary approaches to stop hypertension (DASH) diet v. usual dietary advice on childhood metabolic syndrome: a randomized cross-over clinical trial. Br J Nutr 2013; 110 (12): 2250-9. DOI: 10.1017/S0007114513001724Yang Q, Zhang Z, Kuklina EV et al. Sodium intake and blood pressureamong US children and adolescents. Pediatrics 2012; 130 (4): 611-9. DOI: 10.1542/peds.2011-3870Yang Q, Zhang Z, Kuklina EV et al. Sodium intake and blood pressureamong US children and adolescents. Pediatrics 2012; 130 (4): 611-9. DOI: 10.1542/peds.2011-3870Resnicow K, McMaster F, Bocian A et al. Motivational interviewing and dietary counseling for obesity in primary care: an RCT. Pediatrics 2015; 135 (4): 649-57. DOI: 10.1542/peds.2014-1880Resnicow K, McMaster F, Bocian A et al. Motivational interviewing and dietary counseling for obesity in primary care: an RCT. Pediatrics 2015; 135 (4): 649-57. DOI: 10.1542/peds.2014-1880Broccoli S, Davoli AM, Bonvicini L et al. Motivational interviewing to treat overweight children: 24-month follow-up of a randomized controlled trial. Pediatrics 2016; 137 (1): e20151979. DOI: 10.1542/peds.2015-1979 30/wjc.v6.i5.234Broccoli S, Davoli AM, Bonvicini L et al. Motivational interviewing to treat overweight children: 24-month follow-up of a randomized controlled trial. Pediatrics 2016; 137 (1): e20151979. DOI: 10.1542/peds.2015-1979 30/wjc.v6.i5.234Webb NJ, Shahinfar S, Wells TG et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 2012; 82 (7): 819-26. DOI: 10.1038/ki.2012.210Webb NJ, Shahinfar S, Wells TG et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 2012; 82 (7): 819-26. DOI: 10.1038/ki.2012.210Schaefer F, Litwin M, Zachwieja J et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 2011; 29 (12): 2484-90. DOI: 10.1097/HJH.0b013e32834c625cSchaefer F, Litwin M, Zachwieja J et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 2011; 29 (12): 2484-90. DOI: 10.1097/HJH.0b013e32834c625cChu PY, Campbell MJ, Miller SG, Hill KD. Anti-hypertensive drugs in children and adolescents. World J Cardiol 2014; 6: 234-44.Chu PY, Campbell MJ, Miller SG, Hill KD. Anti-hypertensive drugs in children and adolescents. World J Cardiol 2014; 6: 234-44.Baker-Smith CM, Benjamin DK, Califf RM. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 2010; 87: 668-71. DOI: 10.1038/clpt.2009.231Baker-Smith CM, Benjamin DK, Califf RM. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 2010; 87: 668-71. DOI: 10.1038/clpt.2009.231Schaefer F, Coppo R, Bagga A et al. Efficacy and safety of valsartan in hypertensive children 6 mon to 5 years of age. J Hypertens 2013; 31 (5): 993-1000. DOI: 10.1097/HJH.0b013e32835f5721Schaefer F, Coppo R, Bagga A et al. Efficacy and safety of valsartan in hypertensive children 6 mon to 5 years of age. J Hypertens 2013; 31 (5): 993-1000. DOI: 10.1097/HJH.0b013e32835f5721Trachtman H, Hainer JW, Sugg J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008; 10: 743-50. DOI: 10.1111/j.1751-7176.2008.00022Trachtman H, Hainer JW, Sugg J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008; 10: 743-50. DOI: 10.1111/j.1751-7176.2008.00022Simonett GD, von Vigier RO, Konrad M et al. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol 2006; 21 (10): 1480-2.Simonett GD, von Vigier RO, Konrad M et al. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol 2006; 21 (10): 1480-2.Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005; 20 (5): 631-5.Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005; 20 (5): 631-5.Trachtman H, Frank R, Mahan JD et al. Clinical trial of extended release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18: 548-53. DOI: 10.1007/s00467-003-1134-0Trachtman H, Frank R, Mahan JD et al. Clinical trial of extended release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18: 548-53. DOI: 10.1007/s00467-003-1134-0Karnes JH, Cooper-DeHoff RM. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther 2009; 7: 689-702. DOI: 10.1586/erc.09.31Karnes JH, Cooper-DeHoff RM. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther 2009; 7: 689-702. DOI: 10.1586/erc.09.31Li JS, Flynn JT, Portman R et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr 2010; 157 (2): 282-7. DOI: 10.1016/j.jpeds.2010.02.042Li JS, Flynn JT, Portman R et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr 2010; 157 (2): 282-7. DOI: 10.1016/j.jpeds.2010.02.042Batisky DL, Sorof JM, Sugg J et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 2007; 150 (2): 134-9. DOI: 10.1016/ j.jpeds.2006.09.034Batisky DL, Sorof JM, Sugg J et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 2007; 150 (2): 134-9. DOI: 10.1016/ j.jpeds.2006.09.034Poirier L, Tobe SW. Contemporary use of beta-blocker: clinical relevance of subclassification. Can J Cardiol 2014; 30: S9-15. DOI: 10.1016/j.cjca.2013.12.001Poirier L, Tobe SW. Contemporary use of beta-blocker: clinical relevance of subclassification. Can J Cardiol 2014; 30: S9-15. DOI: 10.1016/j.cjca.2013.12.001Narayan H, Webb DJ. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep 2016; 18 (5): 34. DOI: 10.1007/s11906-016-0643-8Narayan H, Webb DJ. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep 2016; 18 (5): 34. DOI: 10.1007/s11906-016-0643-8Williams B, MacDonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment or drug-resistant hypertension (PATHWAY-2): a randomised, doubleblind, crossover trial. Lancet 2015; 386 (10008): 2059-68. DOI: 10.1016/S0140-6736(15)00257-3Williams B, MacDonald TM, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment or drug-resistant hypertension (PATHWAY-2): a randomised, doubleblind, crossover trial. Lancet 2015; 386 (10008): 2059-68. DOI: 10.1016/S0140-6736(15)00257-3White WB, Turner JR, Sica DA. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., 2013. J Am Soc Hypertens 2014; 8 (10): 743-57. DOI: 10.1016/j.jash.2014.06.005White WB, Turner JR, Sica DA. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., 2013. J Am Soc Hypertens 2014; 8 (10): 743-57. DOI: 10.1016/j.jash.2014.06.005Gartenmann AC, Fossali E, von Vigier RO et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 2003; 64 (4): 1450-4.Gartenmann AC, Fossali E, von Vigier RO et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 2003; 64 (4): 1450-4.

The authors declare that there are no conflicts of interest present.